Log in

NYSE:EWEdwards Lifesciences Stock Price, Forecast & News

$76.94
-0.47 (-0.61 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$76.16
Now: $76.94
$77.64
50-Day Range
$67.13
MA: $72.47
$79.33
52-Week Range
$51.51
Now: $76.94
$82.55
Volume2.22 million shs
Average Volume2.82 million shs
Market Capitalization$47.84 billion
P/E Ratio66.14
Dividend YieldN/A
Beta0.88
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Read More
Edwards Lifesciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.35 billion
Cash Flow$2.02 per share
Book Value$6.17 per share

Profitability

Net Income$1.05 billion

Miscellaneous

Employees13,900
Market Cap$47.84 billion
Next Earnings Date10/28/2020 (Estimated)
OptionableOptionable
$76.94
-0.47 (-0.61 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

How has Edwards Lifesciences' stock been impacted by COVID-19 (Coronavirus)?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EW shares have increased by 16.9% and is now trading at $76.94.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Edwards Lifesciences?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Edwards Lifesciences
.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Edwards Lifesciences
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) released its earnings results on Thursday, July, 23rd. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.19. The medical research company had revenue of $925 million for the quarter, compared to analyst estimates of $782.90 million. Edwards Lifesciences had a net margin of 17.21% and a return on equity of 29.11%.
View Edwards Lifesciences' earnings history
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its third quarter 2020 After-Hours earnings guidance on Thursday, July, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1-1.2 billion, compared to the consensus revenue estimate of $1.04 billion.

What price target have analysts set for EW?

20 equities research analysts have issued 1 year price targets for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $95.00. On average, they anticipate Edwards Lifesciences' share price to reach $84.81 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price.
View analysts' price targets for Edwards Lifesciences
.

Has Edwards Lifesciences been receiving favorable news coverage?

Media coverage about EW stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Edwards Lifesciences
.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Adobe (ADBE), Mastercard (MA), QUALCOMM (QCOM) and CVS Health (CVS).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
  • Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.80%), Sumitomo Mitsui Trust Holdings Inc. (0.57%), Jennison Associates LLC (0.45%), Swiss National Bank (0.40%), UBS Group AG (0.29%) and Railway Pension Investments Ltd (0.27%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences
.

Which major investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Kornitzer Capital Management Inc. KS, SG Americas Securities LLC, Trexquant Investment LP, Fulton Bank N. A., Seven Eight Capital LP, Pendal Group Ltd, and Balasa Dinverno & Foltz LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Scott B Ullem, and William J Phd Link.
View insider buying and selling activity for Edwards Lifesciences
.

Which major investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Jennison Associates LLC, First Trust Advisors LP, Railway Pension Investments Ltd, UBS Group AG, and New York State Common Retirement Fund.
View insider buying and selling activity for Edwards Lifesciences
.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $76.94.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $47.84 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.